- Joined
- May 29, 2025
- Messages
- 608
- Reaction score
- 344
- Gender
- Undisclosed
- Political Leaning
- Independent

Lankford Urges EPA to Investigate Environmental Risks of Abortion Drug Mifepristone - Senator James Lankford
WASHINGTON, DC — US Senator James Lankford (R-OK) and Congressman Josh Brecheen (R-OK) are urging the Environmental Protection Agency (EPA) to investigate the environmental and public health risks of the abortion drug mifepristone, warning that its chemical byproducts may be contaminating the...
The two lists linked above appear to be the first step toward having the EPA target the drug with regulations.The American people deserve to know what contaminants might be present in their drinking water and their potential impacts on public health. We ask for your response to the following questions no later than August 17, 2025. Please provide a separate response to each question, rather than a narrative response.
- Does the EPA believe mifepristone should be considered for regulation under the Safe Drinking Water Act based on potential health and environmental risks? If not, why?
- Has the EPA considered adding mifepristone to UCMR 6? If the agency has not, why?
- How does the EPA select which pharmaceuticals are studied under UCMR?
- Has the EPA considered adding mifepristone to CCL 6?
- Has the EPA conducted or reviewed any research on the presence of mifepristone or its metabolites in drinking water supplies? If not, what gaps currently exist that might prevent this kind of assessment?
- A recent study of insurance claims revealed that over 10% of women experience sepsis, infection, hemorrhaging, or another serious adverse event within 45 days of an abortion using mifepristone—at least 22 times higher than is reported on the drug label. Is the EPA aware of this study? If so, would this data have an impact on the agency’s consideration of adding mifepristone to CCL 6 or UCMR 6?
- Are there existing EPA-approved methods for detecting mifepristone and its active metabolites in water supplies? If not, what resources are needed to develop these testing methods?
- Has the EPA assessed whether exposure to mifepristone and its active metabolites could contribute to hormonal imbalances or infertility in both men and women? Why or why not? If so, has the EPA collaborated with other agencies to make these assessments?
- How are aquatic species affected by exposure to mifepristone and its active metabolites?
Thank you for your attention to this important matter. We look forward to working with you to ensure the health and safety of the American people.